摘要
目的观察伏立康唑在肾移植术后侵袭性肺曲霉菌病中的临床疗效和安全性,为临床治疗提供依据。方法回顾性分析17例肾移植术后侵袭性肺曲霉菌病患者早期应用伏立康唑,同时辅以相关支持治疗。结果 3例确诊患者中,2例治愈;11例临床诊断患者9例治愈;3例拟诊患者2例治愈,平均治愈率为76.5%。结论无论确诊、临床诊断或拟诊的肾移植术后侵袭性肺曲霉菌病,尽早应用广谱抗真菌药物-伏立康唑,均能改善症状并提高治愈率。
OBJECTIVE To observe the clinical efficacy and safety of voriconazole in treatment of invasive pulmonary aspergillosis after renal transplantation so as to provide basis for clinical therapy.METHODS A total of 17 invasive pulmonary aspergillosis patients who used voriconazole after renal transplantation were retrospectively analyzed,the relevant support therapy was supplemented.RESULTS Of 3 diagnosed patients,2 cases were cured,9 of 11 clinically diagnosed patients were cured,2 of 3 suspected patients were cured,the mean cure rate was 76.5%.CONCLUSION No matter is it the diagnosed,clinically diagnosed or suspected invasive pulmonary aspergillosis after renal transplantation,the broad-spectrum antifungal drugs such as voriconazole should be applied in the early stage so as to improve the clinical symptoms and raise the cure rate.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2012年第19期4332-4334,共3页
Chinese Journal of Nosocomiology
关键词
伏立康唑
肾移植
侵袭性肺曲霉菌病
Voriconazole
Renal transplantation
Invasive pulmonary aspergillosis
